Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

被引：0
|
作者：
Arulananda, Surein
John, Thomas
机构：
[1] Olivia Newton John Canc Res Inst, Canc Immunobiol Lab, Heidelberg, Vic, Australia
[2] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[3] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; OSIMERTINIB;
D O I：
10.1016/j.jtho.2019.10.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [21] Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
    Ying Yuan
    Chunwen Tan
    Modan Li
    Hong Shen
    Xuefeng Fang
    Yinghong Hu
    Shenglin Ma
    World Journal of Surgical Oncology, 10
  • [22] Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
    Yuan, Ying
    Tan, Chunwen
    Li, Modan
    Shen, Hong
    Fang, Xuefeng
    Hu, Yinghong
    Ma, Shenglin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [23] Depth of Response to First-Line EGFR TKI Does Not Predict Survival in EGFR-Mutated NSCLC Patients
    Wu, Ting-Hui
    Hsiue, Emily
    Lee, Jih-Hsiang
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S386 - S387
  • [24] Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity
    Jokic, Vera
    Savic-Vujovic, Katarina
    Spasic, Jelena
    Stanic, Nemanja
    Marinkovic, Mladen
    Radosavljevic, Davorin
    Cavic, Milena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 673 - 679
  • [25] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [26] A Phase III Study of Rilertinib Versus Gefitinib as FirstLine Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
    Zhou, C.
    Xiong, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S11 - S11
  • [27] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [28] Lazertinib vs Gefitinib in Treatment-Naive Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis
    Reungwetwattana, T.
    Cho, B. C.
    Lee, K. H.
    Pang, Y. K.
    Fong, C. H.
    Kang, J. H.
    Lee, Y. -G.
    Lim, C. S.
    Danchaivijitr, P.
    Lim, Y. N.
    Lee, Y.
    How, S. H.
    Geater, S.
    Lee, S. S.
    Min, Y. J.
    Kim, J. -H.
    Lee, J. -S.
    Lee, G. -W.
    Soo, R. A.
    Choi, S.
    Lee, S. Y.
    Ahn, M. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S331 - S331
  • [29] Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
    Wang, Q-A.
    Yang, C. T.
    Kuo, C-H. S.
    Hsu, P-C.
    Chang, J. W-C.
    Wu, C-E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1694 - S1694
  • [30] Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
    Buder, A.
    Hochmair, M. J.
    Setinek, U.
    Filipits, M.
    ANNALS OF ONCOLOGY, 2019, 30
12345